IX Biopharma    Last:0.355    -0.005

iX Biopharma

Cashing out. Run road already??

JurongW      ( Date: 26-May-2026 20:32) Posted: Anson Properties sells 2.4 million shares at $0.344 on 19 May. https://links.sgx.com/1.0.0/corporate-announcements/BEJ8HJISNQ6SNAT6/890393__Form%203%20-%20Anson%20Properties%20final.pdf

 

Don't forget. They shot up from 20.5 cents

JurongW      ( Date: 25-May-2026 17:19) Posted: Already broke the trendline resistance (orange line) - not a good sign.  Short term MAs have already sloped down. Now, share price must at least stay within the descending channel. If break the lower channel, it will probably go lower.   PQTPQK      ( Date: 25-May-2026 17:06) Posted: chart  good

 

Anson Properties sells 2.4 million shares at $0.344 on 19 May.

https://links.sgx.com/1.0.0/corporate-announcements/BEJ8HJISNQ6SNAT6/890393__Form%203%20-%20Anson%20Properties%20final.pdf

 

 

Already broke the trendline resistance (orange line) - not a good sign.  Short term MAs have already sloped down.
Now, share price must at least stay within the descending channel. If break the lower channel, it will probably go lower.
 

PQTPQK      ( Date: 25-May-2026 17:06) Posted: chart  good ? JurongW      ( Date: 25-May-2026 16:30) Posted: Trade with care.

 

chart  good ?

JurongW      ( Date: 25-May-2026 16:30) Posted: Trade with care.

 

Trade with care.

 

If one is a believer, now is a good time to pick up cheap.
Have been adding a little around this price.
Just my opinion, please dyodd.

 

Building a base at 34-42 region.
Needs some good news/development for the leg up.
Patience.
Just my opinion. 

 

Unlocking value but still less than Ipo

Newbie85      ( Date: 20-May-2026 19:52) Posted: https://www.nextinsight.net/story-archive-mainmenu-60/949-2026/16723-unlocking-value-ix-biopharma-creates-standalone-us-business-with-potential-spin-off-or-listing Wow A brilliant article on IX!

 

https://www.nextinsight.net/story-archive-mainmenu-60/949-2026/16723-unlocking-value-ix-biopharma-creates-standalone-us-business-with-potential-spin-off-or-listing

Wow A brilliant article on IX!

 

• IX Biopharma announced share allotments involving directors, the CEO and a substantial shareholder on 13 May 2026.
• Directors Teo Woon Keng John and Albert Ho Shing Tung were each allotted 99,051 ordinary shares in lieu of directors&rsquo fees amounting to S$41,750 each.
• Executive Director and CEO Eddy Lee Yip Hang received 1,012,332 ordinary shares arising from the vesting of share awards.
• Substantial shareholder Anson Properties Pte. Ltd. was allotted 1,045,164 ordinary shares, increasing its stake in the Company from 5.96% to 6.03%.

IX Biopharma Ltd. announced changes in shareholdings involving directors, the CEO and a substantial shareholder following the allotment and issuance of new ordinary shares on 13 May 2026.

As approved by shareholders at the Extraordinary General Meeting held on 8 May 2026, Directors Teo Woon Keng John and Albert Ho Shing Tung were each allotted 99,051 ordinary shares, valued at S$41,750 each, in lieu of cash payment for directors&rsquo fees for the period from 1 October 2025 to 31 March 2026. 

Separately, Executive Director and CEO Eddy Lee Yip Hang received 1,012,332 ordinary shares arising from the vesting of share awards, increasing his total interest in the Company from 236.79 million shares to 237.81 million shares. Following the vesting, his total interest in the Company stood at approximately 22.5%. 

In addition, substantial shareholder Anson Properties Pte. Ltd. was allotted 1,045,164 ordinary shares valued at S$440,537, increasing its direct shareholding in IX Biopharma from 62.75 million shares (5.96%) to 63.79 million shares (6.03%).

 

IX Bio. has already making its in road into the US market streamlining its supply chain and manufacturing pathway. Its Wafermine, Petitides and 40 other products will get to sell in US directly and competitively. If successful delivered, there will be a great growth potential.

 

Yes, preparing for the upswing..anytime soon.

Sgvale      ( Date: 12-May-2026 14:28) Posted: Watching this.

 

Watching this.

 

• Ligo Pharma Pte Ltd: iX Biopharma is consolidating its consumer business assets (Australian/HK subsidiaries and the WaferiX DTC platform) into this newly incorporated, 100% owned holding company.
• Asset Split: Ligo will be the vehicle for the US strategy . iX retains the Wafermine drug product, regulatory assets, and US Department of Defence (DoD) contract obligations.
• Financial Impact: The Board confirmed this is an intra-group reorganisation with no material impact on consolidated net tangible assets or earnings per share for the current financial year.

US Strategy & Rationale

• Immediate Commercialization: The 503A/B compounding framework allows for the immediate commercialization of approximately 40 formulations without waiting for FDA approval.
   
• DTC Telehealth: The strategy focuses on building a direct-to-consumer telehealth business. The Board notes that these businesses often trade at valuation premiums and benefit from iX' s patented sublingual technology.
   
• Peptide Opportunity: iX identifies peptides as a major opportunity following the removal of 12 peptides from the restricted list in early 2026. The company claims a first-mover advantage due to its sublingual delivery technology.
   
• Local Manufacturing: The announcement states that US-based manufacturing is operationally necessary to avoid tariff exposure and supply chain uncertainties inherent in shipping from Australia.
   
• Future Exit: The standalone structure is intended to preserve flexibility for future corporate actions, including potential listings on the SGX-ST or NASDAQ.

Joint Venture Update

• Orion & GLD: iX is in advanced discussions with GLD Partners, LP and Orion Specialty Labs to incorporate Orion into the Ligo structure.
   
• Status: GLD would become a co-shareholder of Ligo. Discussions have progressed from a simpler arrangement in November 2025 to a more substantive joint venture structure.

 

Entering in US market is impt..AND what is more eye-popping is their mention of future corporate actions that could be a spin-off on SGX or NAsdaq...HOPE NASDAQ IS THE ONE THEY ARE EYEING...look at Addvalue..iX could be another high potential one.

 

You jealous?

Cindyteoh      ( Date: 11-May-2026 08:10) Posted: Drop to 350 ?  loss making

 

u sold already? u didnt see alot of US companies loss making but stock price still up? stock is forward looking.. not looking on current stats..

DYODD

Cindyteoh      ( Date: 11-May-2026 08:10) Posted: Drop to 350 ?  loss making

 

3. RATIONALE FOR THE RESTRUCTURING The Board believes the restructuring is a necessary and value-creating step. It establishes a purpose-built vehicle to pursue the US consumer health market, which the Board considers the most significant near-term commercial opportunity for iX' s technology, and positions the Company to move quickly and with focus. The key reasons are as follows: &bull iX can enter the large and growing US longevity and lifestyle health market immediately, without waiting for FDA approval. The US 503A/B compounding framework allows iX to commercialise approximately 40 WaferiX-based formulations now, through a pathway that does not exist in any other market iX currently operates in. The US longevity and lifestyle health segment is driven by health-conscious, higher-income consumers who continue to spend on health and wellness regardless of broader economic conditions a segment that is relatively resilient to macroeconomic pressures and one that iX' s product portfolio is directly suited to serve. The scale of this market, and the immediacy of the access the compounding pathway provides, is the primary commercial rationale for the restructuring. &bull The strategic objective is to build WaferiX DTC, a direct-to-consumer telehealth business, not merely a compounding operation. Incumbent DTC telehealth businesses trade at significant valuation premiums to conventional pharmaceutical distribution companies. WaferiX DTC' s advantage is product differentiation: unlike existing platforms that dispense generic, injection-based products, WaferiX formulations are innovative and needle-free, built on patented sublingual technology. &bull Peptides are one of the most significant emerging opportunities in US compounding today. In early 2026, the US authorities removed 12 peptides from the restricted compounding list and scheduled a formal advisory committee review for July 2026 to consider their availability through licensed compounding pharmacies. A favourable outcome could open a substantial new addressable market through the compounding pathway. iX has the technology capable of delivering peptides sublingually, without injection, and several peptides in iX' s own pipeline are among those under active regulatory review. This is a meaningful first-mover advantage in a market that is not yet open. The Board considers it essential to have US manufacturing infrastructure in place before this window opens. No assurance can be given as to the outcome or timing of any regulatory change. &bull US-based manufacturing is operationally necessary to execute this strategy. Supplying the US from Australia is unviable tariff exposure, supply chain uncertainties, and restrictions on active drug ingredients under Australian regulations make it uncompetitive. US-based manufacturing eliminates these constraints. &bull A standalone consumer business structure unlocks value and preserves flexibility for future corporate actions. Ligo creates a focused, investable entity that can be understood and valued independently of iX' s pharmaceutical assets, and preserves flexibility for corporate actions including a spin-off listing on SGX-ST or NASDAQ.

 

Big Huat! Great News on opening up US Market .